- Home
- MINE vs ABEO Comparison
MINE vs ABEO Comparison
Compare MINE & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MINE | ABEO |
|---|---|---|
| Founded | 2019 | 1974 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.9M | 280.2M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | MINE | ABEO |
|---|---|---|
| Price | $4.22 | $5.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 68.1K | ★ 1.0M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.74 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,589.77 |
| P/E Ratio | ★ N/A | $3.90 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $3.65 | $3.93 |
| 52 Week High | $4.34 | $7.54 |
Technical Indicators
Market Signals| Indicator | MINE | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 56.72 | 51.23 |
| Support Level | $3.73 | $4.86 |
| Resistance Level | $4.27 | $5.17 |
| Average True Range (ATR) | 0.28 | 0.20 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 82.49 | 51.43 |
Price Performance
Historical ComparisonAbout MINE Mayfair Gold Corp. Common Shares
Mayfair Gold Corp is a mineral exploration company that is engaged in the acquisition and exploration of mineral properties. It has one material mineral property, the Fenn-Gib Gold Property, located in the Guibord, Munro, Michaud, and McCool Townships in northeast Ontario, which is in the exploration stage.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.